- Home
- MICC vs PRAX Comparison
MICC vs PRAX Comparison
Compare MICC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$18.19
HOLD
Current Price
$296.15
Company Overview
Basic Information| Metric | MICC | PRAX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MICC | PRAX |
|---|---|---|
| Price | $18.19 | $296.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $397.85 |
| AVG Volume (30 Days) | ★ 1.2M | 608.0K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,460,951,263.00 | $7,463,000.00 |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $4.10 | $15,003.90 |
| P/E Ratio | $15.00 | ★ N/A |
| Revenue Growth | 7.33 | ★ 364.98 |
| 52 Week Low | $14.45 | $26.70 |
| 52 Week High | $16.98 | $326.91 |
Technical Indicators
Market Signals| Indicator | MICC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.74 |
| Support Level | N/A | $266.93 |
| Resistance Level | N/A | $326.83 |
| Average True Range (ATR) | 0.00 | 19.30 |
| MACD | 0.00 | -1.92 |
| Stochastic Oscillator | 0.00 | 49.02 |
Price Performance
Historical Comparison MICC
PRAX
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.